The Danish pharmaceutical giant, Novo Nordisk, says that it has been operating in Iran since 2005 based on its “responsibility and commitment to patients with chronic diseases”. ‌But business experts and former employees say that Novo’s close collaboration with a company controlled by Khamenei’s office cracks the image of a responsible and committed pharmaceutical giant. Zamaneh went searching for the pieces of the puzzle to highlight the darker side of Novo’s business in Iran, about which the company prefers to stay silent.